Correspondence 0001193125-24-249279 from Bioventus Inc. (BVS) (CIK 0001665988) (BVS)
Bioventus Inc. (BVS) (CIK 0001665988)
Date: Nov. 1, 2024 · CIK: 0001665988 · Accession: 0001193125-24-249279
AI Filing Summary & Sentiment
File numbers found in text: 333-282836
Letter
Bioventus Inc.
4721 Emperor Boulevard, Suite 100
Durham, NC 27703
November 1, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re:
Bioventus Inc.
Registration Statement on Form S-3
Filed October 25, 2024
File No. 333-282836
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Bioventus Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-282836) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on November 4, 2024 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Jennifer A. Yoon of Latham & Watkins LLP at (617) 880-4540 and that such effectiveness also be confirmed in writing.
Very truly yours,
Bioventus Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Bioventus Inc. 4721 Emperor Boulevard, Suite 100 Durham, NC 27703 November 1, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Bioventus Inc. Registration Statement on Form S-3 Filed October 25, 2024 File No. 333-282836 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Bioventus Inc. (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-282836) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on November 4, 2024 or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to Jennifer A. Yoon of Latham & Watkins LLP at (617) 880-4540 and that such effectiveness also be confirmed in writing. Very truly yours, Bioventus Inc. By: /s/ Anthony D’Adamio Anthony D’Adamio Senior Vice President, General Counsel, Secretary cc: Wesley C. Holmes, Latham & Watkins LLP Jennifer A. Yoon, Latham & Watkins LLP